Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. maintains a strong cash position, which positions the company well for continued operations and development despite regulatory delays. Regulatory feedback indicates that Capricor and the FDA are aligned on the development plan for deramiocel, which is currently in Phase 3 clinical trials for Duchenne muscular dystrophy, suggesting progress toward potential market entry. Additionally, the pending topline data from the HOPE-3 trial, expected in mid-4Q25, combined with positive regulatory discussions, reinforces the company’s favorable outlook and the potential for future product candidates in the exosome space to enhance valuation.

Bears say

Capricor Therapeutics Inc. operates in a challenging environment marked by potential volatility surrounding the upcoming clinical data readouts for its lead product, CAP-1002, specifically from the HOPE-3 trial, which could result in adverse interpretations if the results are negative. The company is facing significant risks related to the success of its clinical trials, as failed or inconclusive results could negatively impact their ability to secure the necessary funding to advance their therapeutics. Furthermore, inconsistencies observed in the secondary and exploratory cardiac-related endpoints raise concerns about the robustness of the clinical findings, further exacerbating the risk profile for investors.

Capricor Therapeutics (CAPR) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.